Law360, New York (March 31, 2010, 3:51 PM ET) -- Alphapharm Pty. Ltd. has agreed to drop antitrust counterclaims against Pozen Inc., though the battle rages on over whether it and several other generics makers infringed Pozen's patents for migraine treatment Treximet.
The joint motion — filed Tuesday in the U.S. District Court for the Eastern District of Texas — calls for the dismissal of Alphapharm's antitrust counterclaims without prejudice.
The motion did not provide any additional explanation for the move, and attorneys for Pozen and Alphapharm were not immediately available for comment Wednesday.
Pozen's infringement...
Alphapharm Drops Antitrust Claims In Treximet IP Suit
To view the full article, take a free trial now.
